<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02647762</url>
  </required_header>
  <id_info>
    <org_study_id>CF101-301RA</org_study_id>
    <nct_id>NCT02647762</nct_id>
  </id_info>
  <brief_title>CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Active- and Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of CF101 Compared to Methotrexate in the Treatment of Early Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Can-Fite BioPharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Fite BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will test the hypothesis that the administration of CF101, a novel
      anti-inflammatory agent, to patients with rheumatoid arthritis will relieve signs and
      symptoms of the disease. CF101 effect will be in comparison to MTX in this study population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind, active- and placebo-controlled, parallel-group study
      in subjects with clinically active RA but who are MTX-na√Øve. Subjects who meet enrollment
      criteria will be randomized to 1 of 4 groups in a 2:2:2:1 ratio: CF101 1 mg, CF101 2 mg, MTX,
      or matching placebo tablets. CF101 or matching placebo will be administered every 12 hours
      for up to 24 weeks on treatment. MTX or matching placebo will be administered once a week
      Screening examinations will occur within 6 weeks prior to dosing. The following conventional
      drugs for RA treatment must be stable for the respective designated periods prior to the
      Screening Visit and must remain so during protocol participation: nonsteroidal
      anti-inflammatory drugs (NSAIDS), and corticosteroids for &gt;1 month. All subjects will receive
      oral folate (minimum dose 5 mg/week) or oral folinic acid (up to 10 mg/week), based on the
      Investigator's preference.

      Disease activity will be assessed using swollen and tender joint counts, erythrocyte
      sedimentation rate (ESR), and CRP. Efficacy will be assessed by Disease Activity Score 28
      using the erythrocyte sedimentation rate (DAS28-ESR), ACR response criteria and European
      League Against Rheumatism (EULAR) response criteria : swollen and tender joint counts,
      physician global assessment (by visual analog scale, patient global assessment , patient
      reported pain, a Health Assessment Questionnaire (HAQ) Disability Index (DI) , Westergren ESR
      levels, and CRP levels. Assessments will occur at Screening, Baseline (Week 0), and Weeks 4,
      8, 12 16, 20, and 24. At Weeks 12, 16, and 20, any subject who has not experienced at least
      20% improvement in both the number of swollen and number of tender joints will be given
      rescue therapy with open-label oral MTX and followed through Week 24.

      PK will be assessed in a subgroup of approximately 100 subjects at Week 0, Week 8, and Week
      12. All subjects in the PK cohort will have samples collected for PK at time 0, and each
      subject will have additional samples drawn at 2 of the following post-dose time points: 1, 2,
      3, 4, 6, and 8 hours. Whole blood sample for A3AR expression will be assessed in
      approximately 100 subjects at selected sites at Screening and Week 12, or end of dosing, if
      occurring before Week 12.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of oral CF101, BID for 12 weeks to subjects with active rheumatoid arthritis (RA) relative to oral methotrexate (MTX) as assessed by the proportion of subjects achieving a Disease Activity Score (DAS) of Low Disease Activity (LDA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of subjects achieving Disease Activity Score (DAS) (based on Erythrocyte Sedimentation Rate) of Low Disease Activity (&lt;3.2, where lower scores indicate lower disease activity) at Week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess the adverse event profile of daily oral CF101 under the conditions of the trial</measure>
    <time_frame>24 weeks</time_frame>
    <description>Nature, incidence and severity of treatment-emergent adverse events (TEAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe the pharmacokinetics (PK) of CF101 under the conditions of the trial</measure>
    <time_frame>24 weeks</time_frame>
    <description>Plasma CF101 levels will be determined</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the efficacy of oral CF101 when administered daily for 24 weeks to subjects with active RA relative to oral MTX, as assessed by the proportion of subjects achieving DAS remission</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change and percent change from baseline in DAS28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the relationship between whole blood adenosine A3 receptor (A3AR) expression and treatment response</measure>
    <time_frame>24 weeks</time_frame>
    <description>A3AR expression will be assessed on whole blood samples</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>CF101 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF101 1mg, orally q12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CF101 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CF101 2mg, orally q12 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTX once weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control , orally q12 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101 1 mg</intervention_name>
    <description>CF101 tablets, 1mg BID for 12 weeks</description>
    <arm_group_label>CF101 1mg</arm_group_label>
    <other_name>IB-MECA</other_name>
    <other_name>Piclidenosone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF101 2 mg</intervention_name>
    <description>CF101 tablets, 2 mg BID for 12 weeks</description>
    <arm_group_label>CF101 2mg</arm_group_label>
    <other_name>IB-MECA</other_name>
    <other_name>Piclidenosone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets, 1mg BID for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.</description>
    <arm_group_label>MTX once weekly</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females ages 18-75 years.

          2. Meet the criteria of the American College of Rheumatology for RA (Arnett FC et al.
             Arthritis Rheum 1988;31:315-324, Appendix 1).

          3. Not bed- or wheelchair-bound.

          4. Active RA, as indicated by EULAR Disease Activity Score (Fransen, vanRiel, 2005,
             DAS28, 2015) (DAS28) &gt;3.2.

          5. Demonstrate at least 6 swollen and at least 6 tender joints.

          6. If taking an NSAID, dose has been stable for at least 1 month prior to the Screening
             Visit, and will remain unchanged during protocol participation.

          7. If taking an oral corticosteroid, dose is &lt;10 mg/day prednisone or equivalent, has
             been stable for at least 1 month prior to the Screening Visit, and will remain
             unchanged during protocol participation.

          8. In the Investigator's opinion, the ability to understand the nature of the study and
             any hazards of participation, and to communicate satisfactorily with the Investigator
             and to participate in, and to comply with, the requirements of the entire protocol.

          9. Negative Screening serum pregnancy test for female subjects of childbearing potential.

         10. Females of childbearing potential must utilize, throughout the course of the trial, 2
             methods of contraception deemed adequate by the Investigator (for example, oral
             contraceptive pills plus a barrier method).

         11. All aspects of the protocol explained and written informed consent obtained.

        Exclusion Criteria:

          1. Prior receipt of MTX.

          2. Prior receipt of &gt;1 regimen of synthetic small-molecule DMARDs.

          3. Receipt of any non-MTX synthetic small-molecule DMARDs (including but not limited to
             sulfasalazine, chloroquine/hydroxychloroquine, azathioprine, and/or leflunomide) for
             at least 1 month prior to the Screening Visit or concomitantly during the trial.

          4. Receipt of tofacitinib at any time during the 4-week period prior to the Screening
             Visit or concomitantly during the trial.

          5. Receipt of a biologic anti-rheumatic agent (including, but not limited to, etanercept,
             abatacept, infliximab, golimumab, adalimumab, tocilizumab, certolizumab, and
             rituximab) at any time prior to or concomitantly during the trial.

          6. Levels of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibody
             that are both &gt;3 times the upper limit of the laboratory normal value at the Screening
             Visit.

          7. Receipt of parenteral or intra-articular corticosteroids during the 1 month prior to
             the Screening Visit.

          8. Participation in a previous trial CF101 trial.

          9. Presence or history of uncontrolled arterial hypertension or symptomatic hypotension.

         10. Heart disease which is, in the Investigator's judgment, clinically significant or
             unstable, including coronary artery disease, congestive heart failure, uncontrolled
             arrhythmia, or other significant findings on Screening electrocardiogram (ECG).

         11. Clinical laboratory abnormalities at the Screening Visit as follows:

               1. Hemoglobin level &lt;9.0 gm/dL

               2. Platelet count &lt;125,000/mm3

               3. White blood cell (WBC) count &lt;3000/mm3

               4. Serum creatinine level outside the central laboratory's normal limits

               5. Liver aminotransferase (ALT and/or AST) levels greater than 2 times the central
                  laboratory's upper limit of normal.

         12. Known or suspected immunodeficiency or human immunodeficiency virus positivity.

         13. Pregnancy, lactation, or inadequate contraception as judged by the Investigator.

         14. Participation in another investigational drug or vaccine trial concurrently or within
             30 days prior to Screening.

         15. Active drug or alcohol dependence.

         16. History of malignancy within the past 2 years (excluding excised basal or squamous
             cell carcinoma of the skin).

         17. Significant acute or chronic medical or psychiatric illness that, in the judgment of
             the Investigator, could compromise subject safety, limit the subject's ability to
             complete the study, and/or compromise the objectives of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael H Silverman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Can-Fite BioPharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zivit Harpaz</last_name>
    <phone>972-3-9241114</phone>
    <email>zivit@canfite.co.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #252</name>
      <address>
        <city>Banja Luka</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #253</name>
      <address>
        <city>Mostar</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #251</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #254</name>
      <address>
        <city>Sarajevo</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #255</name>
      <address>
        <city>Tuzla</city>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #751</name>
      <address>
        <city>Barrie</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #309</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #302</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #581</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #582</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #583</name>
      <address>
        <city>Chisinau</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #401</name>
      <address>
        <city>Bia≈Çystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #402</name>
      <address>
        <city>Bochnia</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #403</name>
      <address>
        <city>Pozna≈Ñ</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #404</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #405</name>
      <address>
        <city>Zamo≈õƒá</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #559</name>
      <address>
        <city>BrƒÉila</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #551</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #552</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #553</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #556</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #558</name>
      <address>
        <city>Constan≈£a</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #557</name>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #560</name>
      <address>
        <city>Ia≈üi</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #561</name>
      <address>
        <city>Ia≈üi</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #555</name>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #554</name>
      <address>
        <city>Timi≈üoara</city>
        <country>Romania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #211</name>
      <address>
        <city>Belgrad</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #212</name>
      <address>
        <city>Belgrad</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #216</name>
      <address>
        <city>Leskovac</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #215</name>
      <address>
        <city>Ni≈°</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #213</name>
      <address>
        <city>Novi Sad</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #217</name>
      <address>
        <city>Vranje</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Can-Fite Investigational Site #214</name>
      <address>
        <city>≈†abac</city>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>Moldova, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Serbia</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2016</study_first_posted>
  <last_update_submitted>March 29, 2018</last_update_submitted>
  <last_update_submitted_qc>March 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

